Niemann Pick C (NPC): monitoring and treatment
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Niemann Pick C (NPC): monitoring and treatment. Psychiatric symptoms, Cognitive function, Eye movement disorders. Fully referenced neurology checklist.
6-12 monthly assessments
- Psychiatric symptoms
- Cognitive function
- Eye movement disorders
- Swallowing function: in children
12 monthly assessments
Locked: subscribe to see this section.
Miglustat
Locked: subscribe to see this section.
Other treatments
Locked: subscribe to see this section.
Investigational treatments
Locked: subscribe to see this section.
References
- Geberhiwot T, Moro A, Dardis A, et al; International Niemann-Pick Disease Registry (INPDR). Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis 2018; 13:50.
- Bowman EA, Walterfang M, Abel L, Desmond P, Fahey M, Velakoulis D. Longitudinal changes in cerebellar and subcortical volumes in adult-onset Niemann-Pick disease type C patients treated with miglustat. J Neurol 2015; 262:2106-2114.
- Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 2017; 390:1758-1768.
- Bremova-Ertl T, Ramaswami U, Brands M, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C. N Engl J Med 2024; 390:421-431.
